Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software

NCT ID: NCT04980989

Last Updated: 2021-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

765 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-15

Study Completion Date

2021-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference which was the primary end-point. At baseline, 6 months and 12 months the patients answered the other questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm.

The primary end point was to find out patient preference for the modality of surveillance. Secondary endpoints were patient satisfaction, symptoms, quality of life and cost of follow-up during surveillance modalities.

At 12 months the patients were asked their preference for the follow-up modality of early breast cancer. At baseline, 6 months and 12 months the patients answered the other questionnaires on quality of life, symptoms, patient satisfaction and use of other health-care services. Information on the cost of follow-up was gathered from the hospital and other registries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer, Early-Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference. At baseline, 6 months and 12 months the patients answered the other questionnaires on patient satisfaction, quality of life, symptoms and use of other healthcare services.
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mobile software

Patient with early breast cancer were followed-up by mobile software for the first six months. At six months they crossed-over to be followed-up by telephone calls for the next six months.

Group Type EXPERIMENTAL

Mobile software for follow-up of early breast cancer

Intervention Type DEVICE

The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer

Telephone calls

Patient with early breast cancer were followed-up by telephone calls for the first six months. At six months they crossed-over to be followed-up by mobile software for the next six months.

Group Type ACTIVE_COMPARATOR

Mobile software for follow-up of early breast cancer

Intervention Type DEVICE

The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mobile software for follow-up of early breast cancer

The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Noona mobile software

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with early breast cancer after primary treatment including also radiotherapy (the patients were randomized at the final visit of radiotherapy)

Exclusion Criteria

* not able to use a computer
* another malignancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Helsinki

OTHER

Sponsor Role collaborator

Noona Healthcare

UNKNOWN

Sponsor Role collaborator

Helsinki University Central Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Johanna Mattson

Physician-in-Chief

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johanna Mattson, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Helsinki University Central Hospital

Carl Blomqvist, Professor

Role: STUDY_CHAIR

Helsinki University Central Hospital

Johanna Mattson, MD, PhD

Role: STUDY_DIRECTOR

Helsinki University Central Hospital

References

Explore related publications, articles, or registry entries linked to this study.

Mattson J, Peltola M, Poikonen-Saksela P, Hermanson T, Their J, Farkkila N, Roine R, Blomqvist C. Digital solution in the follow-up of early breast cancer a randomized study. Acta Oncol. 2023 May;62(5):513-521. doi: 10.1080/0284186X.2023.2212409. Epub 2023 May 16.

Reference Type DERIVED
PMID: 37190970 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

112/13/03/02/2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FAST-FORWARD vs HAI5
NCT06345534 RECRUITING NA